EUVIMEDEUVIMED entdecken
Crossref

Prognostic Significance of PET− SUV max in Patients Undergoing Resection of Hepatocellular Carcinoma >3 cm: A Retrospective Analysis

Takuma Ishikawa, Shinji Itoh, Yoshiyuki Kitamura, Norifumi Iseda, Shohei Yoshiya, Takashi Motomura, Takeo Toshima, Takuro Isoda, Kousei Ishigami, Tomoharu Yoshizumi

Anticancer Research · 2026

DOI: 10.21873/anticanres.18401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Takuma Ishikawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Positron-Emission Tomography.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Hepatocellular carcinoma (HCC) >3 cm often recurs after resection, indicating a need for better risk stratification. The 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) maximum standardized uptake value (SUVmax) reflects tumor aggressiveness. We evaluated the prognostic significance of preoperative FDG-PET SUVmax in patients with resectable initial HCC >3 cm. PATIENTS AND METHODS: This retrospective analysis included 136 patients who underwent curative resection for HCC >3 cm between 2012 and 2021 with preoperative FDG-PET imaging. Patients were classified into low- and high-uptake groups based on tumor SUVmax. Associations between FDG-PET findings and clinicopathological factors were analyzed. RESULTS: Patients with high SUVmax had significantly worse overall survival than those with low SUVmax (49.2% vs. 90.0%, p 3 cm and, when combined with serum alpha-fetoprotein, may enhance prediction of MVI. These findings support incorporating metabolic imaging into preoperative risk models to guide management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPositron-Emission TomographyHumansFemaleRetrospective StudiesPrognosisFluorodeoxyglucose F18MaleMiddle AgedAgedRadiopharmaceuticalsAdult

Stichwörter der Autor:innen

Hepatocellular carcinomaalpha-fetoproteinimaging biomarkermicrovascular invasionpositron emission tomography

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; itoh.shinji.453@m.kyushu-u.ac.jp.
  • Department of Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Zitieren

APA

Ishikawa, T., Itoh, S., Kitamura, Y., Iseda, N., Yoshiya, S., Motomura, T., Toshima, T., Isoda, T., Ishigami, K., & Yoshizumi, T. (2026). Prognostic Significance of PET− SUV max in Patients Undergoing Resection of Hepatocellular Carcinoma >3 cm: A Retrospective Analysis. Anticancer Research. https://doi.org/10.21873/anticanres.18401

Vancouver

Ishikawa T, Itoh S, Kitamura Y, Iseda N, Yoshiya S, Motomura T, et al. Prognostic Significance of PET− SUV max in Patients Undergoing Resection of Hepatocellular Carcinoma >3 cm: A Retrospective Analysis. Anticancer Research. 2026. doi:10.21873/anticanres.18401

BibTeX
@article{Ishikawa2026,
  author = {Ishikawa, Takuma and Itoh, Shinji and Kitamura, Yoshiyuki and Iseda, Norifumi and Yoshiya, Shohei and Motomura, Takashi and Toshima, Takeo and Isoda, Takuro and Ishigami, Kousei and Yoshizumi, Tomoharu},
  title = {Prognostic Significance of PET− SUV max in Patients Undergoing Resection of Hepatocellular Carcinoma >3 cm: A Retrospective Analysis},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18401}
}
Kostenlos starten →